CL2021003353A1 - Tratamiento conjunto antineoplásico. - Google Patents

Tratamiento conjunto antineoplásico.

Info

Publication number
CL2021003353A1
CL2021003353A1 CL2021003353A CL2021003353A CL2021003353A1 CL 2021003353 A1 CL2021003353 A1 CL 2021003353A1 CL 2021003353 A CL2021003353 A CL 2021003353A CL 2021003353 A CL2021003353 A CL 2021003353A CL 2021003353 A1 CL2021003353 A1 CL 2021003353A1
Authority
CL
Chile
Prior art keywords
joint
antineoplastic treatment
antineoplastic
treatment
inhibitor
Prior art date
Application number
CL2021003353A
Other languages
English (en)
Inventor
Marco Hans Hofmann
Michael Gmachl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2021003353A1 publication Critical patent/CL2021003353A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención describe tratamientos antineoplásicos que comprenden el uso de un inhibidor de SOS1 en combinación con un inhibidor de MEK, cada uno como se describe en la presente.
CL2021003353A 2019-06-19 2021-12-15 Tratamiento conjunto antineoplásico. CL2021003353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181360 2019-06-19

Publications (1)

Publication Number Publication Date
CL2021003353A1 true CL2021003353A1 (es) 2022-09-30

Family

ID=66999660

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003353A CL2021003353A1 (es) 2019-06-19 2021-12-15 Tratamiento conjunto antineoplásico.

Country Status (12)

Country Link
US (1) US20220249492A1 (es)
EP (1) EP3986408A1 (es)
JP (1) JP2022537044A (es)
KR (1) KR20220024191A (es)
CN (1) CN114375202A (es)
AU (1) AU2020296914A1 (es)
BR (1) BR112021024532A2 (es)
CA (1) CA3142239A1 (es)
CL (1) CL2021003353A1 (es)
MX (1) MX2021016137A (es)
TW (1) TW202114683A (es)
WO (1) WO2020254451A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51290A (fr) * 2017-12-21 2021-03-31 Boehringer Ingelheim Int Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1
WO2022157629A1 (en) 2021-01-19 2022-07-28 Lupin Limited Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
CN113200981A (zh) * 2021-02-10 2021-08-03 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
WO2022212546A1 (en) * 2021-03-31 2022-10-06 Acerand Therapeutics (Usa) Limited Pyridopyrimidinone compounds
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
EP4337678A1 (en) * 2021-05-12 2024-03-20 Revolution Medicines, Inc. Use of sos1 inhibitors with mtor inhibitors to treat cancers
CA3227026A1 (en) * 2021-08-03 2023-02-09 Evopoint Biosciences Co., Ltd. Fused ring compound, pharmaceutical composition, and application thereof
CN115417868B (zh) * 2021-09-13 2024-04-02 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
WO2023041049A1 (zh) * 2021-09-17 2023-03-23 江苏先声药业有限公司 作为sos1抑制剂的杂环化合物及其用途
CN115057847B (zh) * 2022-07-26 2024-01-26 山东百启生物医药有限公司 一种4,6-二氯-5-(1,3-二氧戊环-2-基)-2-甲基嘧啶的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24335B1 (es) 2012-03-14 2018-04-03 Lupin Ltd Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
WO2018115380A1 (en) * 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
MA51290A (fr) 2017-12-21 2021-03-31 Boehringer Ingelheim Int Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1

Also Published As

Publication number Publication date
CN114375202A (zh) 2022-04-19
MX2021016137A (es) 2022-02-21
AU2020296914A1 (en) 2021-12-23
US20220249492A1 (en) 2022-08-11
TW202114683A (zh) 2021-04-16
EP3986408A1 (en) 2022-04-27
CA3142239A1 (en) 2020-12-24
BR112021024532A2 (pt) 2022-05-24
JP2022537044A (ja) 2022-08-23
WO2020254451A1 (en) 2020-12-24
KR20220024191A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2021003353A1 (es) Tratamiento conjunto antineoplásico.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2023002946A1 (es) Tratamiento conjunto antineoplásico
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2019002742A1 (es) Tratamiento conjunto antineoplásico.
CL2019001554S1 (es) Automóvil.
CL2015002369A1 (es) Uso de linagliptina en terapia antidiabética cardio y renoprotectora
PE20180260A1 (es) Metodos y kits para tratar la depresion
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
DK3740504T3 (da) CD70 kombinationsterapi
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
CL2019002232S1 (es) Automóvil.
CL2020001201S1 (es) Automóvil.
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer
CL2020000174S1 (es) Automóvil.
CL2018001276A1 (es) Composición antimicrobiana para el revestimiento de superficies
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
CL2018002638A1 (es) Ambrisentan para uso en el tratamiento de insuficiencia renal aguda
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
BR112018008639A2 (pt) recorte adesivo com espaços vazios
UY38472A (es) Moduladores de la expresión de foxp3
CL2019003037A1 (es) Combinaciones fungicidas.
Dykstra Liberation psychology—A history for the future.